What are the key sales KPIs for the Pharmacy Benefit Manager (PBM) industry in 2027?

👁 0 views📖 2,131 words⏱ 10 min read5/30/2026

Direct Answer

The nine KPIs that actually run a Pharmacy Benefit Manager (PBM) business in 2027 are: Scripts Dispensed (30-day adjusted), Rebate Retention vs Pass-Through %, Generic Dispensing Rate (GDR %), Specialty Pharmacy Mix %, Client Retention % (employer / health plan), PMPM Admin Fee ($/member/month), Formulary Adherence %, Mail-Order Penetration %, and 340B Contract-Pharmacy Revenue ($).

Together they answer the only three questions a PBM CFO cares about: are you growing claim volume, are you keeping the spread (and surviving the pivot to cost-plus), and are you retaining the employer and health-plan book under a 100% rebate pass-through regime.

TL;DR
— The Big-3 PBMs — CVS Caremark, Express Scripts, OptumRx — still process ~80% of U.S. Equivalent prescription claims, but the 2026 Consolidated Appropriations Act and the FTC settlement with Express Scripts force 100% rebate pass-through and a cost-plus reimbursement path that compresses traditional rebate-retention economics.
Healthy GDR is 90%+, specialty mix is 50%+ of spend on under 2% of scripts, client retention should be 90%+ annually, and PMPM admin fees are migrating from $0.50–$2 (rebate-funded) to $5–$15 (cost-plus). Track claim volume and rejections daily, formulary adherence and GDR weekly, retention and PMPM monthly, and re-run the rebate-vs-cost-plus mix model quarterly — that is the operating cadence every PBM CFO is now running.

Why PBMs Work Differently

Three-sided economics on every script. A PBM sits between plan sponsors (employers, health plans, Medicare Part D), drug manufacturers, and dispensing pharmacies. Revenue comes from four pools: admin fees from the plan sponsor (PMPM), rebate retention from manufacturers, spread on pharmacy reimbursement (paid pharmacy < charged plan), and dispensing margin from owned mail-order and specialty pharmacies.

Historically the rebate and spread pools dwarfed PMPM fees — the 2026 reform package is the deliberate inversion of that mix. CVS Caremark, Express Scripts (Cigna Evernorth), and OptumRx (UnitedHealth) processed roughly 80% of U.S. 30-day adjusted claims in 2025: CVS Caremark at ~1.9B claims, Express Scripts pulling ahead after the Centene contract, OptumRx losing the CalPERS book to Caremark for 2026.

Specialty pharmacy is the profit pool. Drug Channels Institute pegged 2025 specialty pharmaceutical dispensing at ~$293.4B, up 9.6% year over year — and the top three specialty pharmacies, all owned by the Big-3 PBMs, captured roughly two-thirds of pharmacy-dispensed specialty revenue.

Specialty scripts are under 2% of total volume but well over 50% of plan drug spend, and they carry the highest gross margin per script in the entire model. That is why every reform conversation in 2026 lands on the same vertical integration question: PBM, mail-order, specialty pharmacy, and (at CVS and Optum) the insurer itself.

Regulatory reset to cost-plus and pass-through. The Consolidated Appropriations Act of 2026 requires that ERISA group health plans receive 100% of manufacturer rebates from PBMs and their affiliated rebate aggregators. The FTC settlement with Express Scripts (February 2026) requires Express Scripts to move to cost-plus pharmacy reimbursement and eliminate spread pricing and rebate retention.

CVS Caremark's "TrueCost" and OptumRx's "Cost Clarity" are the in-house responses, with full implementation targeted by 2028. The CFO question is no longer "how much rebate do we retain" — it is "what PMPM admin fee replaces it, and does the client still renew."

Mark Cuban Cost Plus Drugs and the disintermediation threat. Cuban's Cost Plus Drug Company has rewritten the price-transparency narrative — every generic posted at acquisition-cost-plus-15%-plus-$3-pharmacy-fee-plus-$5-shipping. The FTC interim reports flagged that six PBMs control more than 90% of the U.S.

Prescription drug market. The effect is not Cuban taking 30% market share — it is forcing the Big-3 to underwrite explicit cost-plus product (Caremark TrueCost, OptumRx Cost Clarity) and to defend GDR economics inside their own books rather than at the network edge.

The 9 KPIs, In Depth

1. Scripts Dispensed (30-day adjusted, millions). The volume number. Express Scripts processes ~2B+ 30-day adjusted claims annually, CVS Caremark ~1.9B (down 0.9% in 2025), OptumRx ~1.5B.

Reported by channel (retail network, mail, specialty) and by line of business (commercial, Medicare Part D, Medicaid, exchange). Volume drift below -3% is the leading indicator of contract loss.

2. Rebate Retention vs Pass-Through % (basis points retained). Pre-reform, large PBMs retained 10–30% of negotiated rebates. Under the 2026 CAA and DOL rule, ERISA group plans receive 100% of manufacturer rebates from PBMs and their rebate aggregators.

The KPI is now bifurcated: legacy retention book in run-off vs new pass-through plus PMPM admin fee book in run-on. The cash-flow gap is the single biggest source of 2026–2027 PBM margin compression.

3. Generic Dispensing Rate (GDR %). Generic fills divided by total prescriptions. Industry average is in the high 80s; best-in-class PBMs run 90%+. Every 1% increase in GDR is roughly a 5% reduction in gross plan drug spend, per published PBM benchmarking literature. The metric is contractually guaranteed on most large-employer PBM deals.

4. Specialty Pharmacy Mix % (% of spend / % of scripts). Specialty scripts are under 2% of total prescription volume but 50%+ of total spend, dispensing ~$293.4B in 2025 (up 9.6%). The top-3 specialty pharmacies, all PBM-owned, captured roughly two-thirds of pharmacy-dispensed specialty revenue.

Specialty mix and specialty steerage to owned pharmacy is the single biggest gross-margin lever in the model.

5. Client Retention % (employer / health plan, annual). Annual retention of plan-sponsor lives. Best-in-class is 95%+; industry average is 90–93%.

Major contract movements (Anthem leaving Express Scripts in 2019, CalPERS leaving OptumRx for Caremark in 2026) move billions in scripts in one renewal cycle. Track gross retention separately from net (which masks downsell).

6. PMPM Admin Fee ($/member/month). Admin fee per covered member per month. Historically $0.50–$2 PMPM under rebate-subsidized models. Under cost-plus and 100% pass-through, the replacement fee migrates to $5–$15 PMPM. The pricing pivot is the single most-scrutinized line item in every 2026–2027 RFP from Aon, Mercer, and WTW.

7. Formulary Adherence % (preferred-drug fill rate). Share of scripts filled at the preferred-formulary tier. Above 85% is healthy; below 75% means the formulary is leaking value through prior-auth failures, non-preferred fills, and physician override. Drives the manufacturer rebate yield that funds the rest of the model.

8. Mail-Order Penetration % (90-day mail vs retail). Share of maintenance-medication scripts dispensed through mail (90-day fills). Big-3 PBMs target 25–35% mail penetration on maintenance categories because mail margins are 200–400 bps higher than retail-network spread.

Lower mail-order utilization usually correlates with a weaker incentive design at the plan-sponsor level.

9. 340B Contract-Pharmacy Revenue ($). Revenue from administering 340B contract-pharmacy programs for covered entities (DSH hospitals, FQHCs). The fastest-growing PBM-adjacent revenue stream, but also the most regulatory-volatile — manufacturer restrictions on 340B contract pharmacies (Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, etc.) have cut covered-entity revenue at hundreds of safety-net providers since 2023.

flowchart TD A[Plan Sponsor Contract] --> B[PMPM Admin Fee + Pass-Through Rebates] A --> C[Network of Retail Pharmacies] A --> D[Owned Mail-Order Pharmacy] A --> E[Owned Specialty Pharmacy] C --> F[Scripts Dispensed] D --> F E --> F F --> G{Generic vs Brand vs Specialty} G -->|Generic 90%| H[Lowest Cost High GDR Bonus] G -->|Brand 8%| I[Manufacturer Rebate Yield] G -->|Specialty under 2%| J[50%+ of Plan Spend] H --> K[Plan Sponsor Renewal Decision] I --> K J --> K K -->|Retain 90-95%| A K -->|Lose 5-10%| L[Volume Loss to Competitor PBM] J --> M[Specialty Steerage to Owned Pharmacy] M --> N[Highest Gross Margin Pool] N --> O[Reinvest in Formulary + Tech] O --> A

Real Operators

CVS Caremark (CVS Health) is the volume leader — ~1.9B 30-day adjusted claims in 2025, ~31% market share, anchored to CVS retail, Caremark mail, and CVS Specialty, with CalPERS rejoining the book in 2026 and a "TrueCost" cost-plus pricing program launching system-wide. Express Scripts (Cigna Evernorth) is the share-gainer — added the Centene book, pulling ahead in 30-day equivalent claims, and is the named defendant in the FTC February 2026 settlement that mandates cost-plus reimbursement and the end of spread pricing.

OptumRx (UnitedHealth Group) is the third pillar — ~20% market share, "Cost Clarity" cost-plus offering, lost CalPERS but added other large employer wins. Humana Pharmacy Solutions runs the captive PBM for Humana's Medicare Advantage book. Prime Therapeutics is the Blues-owned PBM serving ~30M Blue Cross Blue Shield lives.

Navitus Health Solutions is the largest pass-through PBM, marketed as the transparent alternative. MedImpact Healthcare Systems is the largest privately held PBM, regional and health-plan focused. Capital Rx (now Judi Health) and Rightway are the venture-backed pass-through challengers winning mid-market employer business.

Mark Cuban Cost Plus Drug Company is not a PBM in the traditional sense but the disintermediation pressure on Big-3 generic economics is real.

Failure Modes

The four that kill PBMs. (1) Rebate-retention denial — modeling 2027 and 2028 P&L on legacy rebate retention assumptions when the CAA and FTC settlement explicitly forbid them is a 200–400 bps EBITDA miss. (2) Specialty steerage litigation risk — over-aggressive steerage to owned specialty pharmacy invites state attorney general action and ERISA fiduciary suits from plan sponsors.

(3) Client-concentration cliff — when one health-plan or PBM-aggregator contract is 15%+ of book (Centene to Express Scripts, Anthem in prior cycles), a single non-renewal moves billions of scripts in one quarter. (4) PMPM admin-fee underpricing — replacing rebate retention with PMPM fees that are too low to recover the cost gap and discovering the gap only at the next true-up.

Reporting Cadence

Daily: scripts processed, network rejections, prior-auth turnaround, specialty pharmacy fill rates. Weekly: GDR by client, formulary adherence by client, mail-order penetration, member-services service-level agreements. Monthly: PMPM admin fee vs target by client, specialty mix and gross margin by therapy area, rebate accrual vs pass-through actuals, client-level P&L.

Quarterly: retention pipeline (renewal/RFP), regulatory exposure (FTC, state PBM laws, CMS Part D guidance), 340B contract pipeline, full P&L by line of business for the earnings call.

flowchart TD A[Daily Telemetry] --> B[Scripts + Rejections + PA Turnaround + Specialty Fill] B --> C[Weekly Operating Review] C --> D[GDR by Client + Formulary Adherence + Mail Penetration + SLAs] D --> E[Monthly Business Review] E --> F[PMPM Actual vs Target + Specialty Margin + Rebate Pass-Through + Client P&L] F --> G[Quarterly Earnings + Board] G --> H[Retention Pipeline + Regulatory + 340B + LOB P&L] H --> I[Re-forecast PMPM Pricing + Specialty Steerage + Cost-Plus Mix] I --> A

30/60/90 Day Plan

Days 1–30: instrument the nine KPIs end-to-end. Reconcile 30-day adjusted claim counts across the adjudication platform (RxClaim or equivalent), finance, and the rebate-aggregator reporting — they will disagree on day one and the reconciliation gap is the first finding. Establish GDR, specialty mix, and PMPM-actual baselines per client.

Days 31–60: build the cost-plus migration model. Run client-by-client P&L under three scenarios: legacy rebate-retention, 100% pass-through with current PMPM fee, and 100% pass-through with re-priced PMPM at $8–$12. Identify the bottom-decile clients where the math does not work and brief sales on re-pricing or non-renewal.

Days 61–90: stand up the regulatory exposure dashboard. Map every contract against CAA 2026, the FTC Express Scripts consent order, state PBM transparency laws (Texas, Florida, Iowa, Oklahoma, Arkansas), and CMS Part D guidance. Re-baseline 340B contract-pharmacy revenue under updated manufacturer restrictions and present the new operating model to the CFO with monthly checkpoints.

FAQ

Is rebate retention dead in 2027? Inside ERISA group health, effectively yes — the CAA 2026 100% pass-through mandate plus the FTC Express Scripts settlement collapse the traditional retention economics. Outside ERISA (Medicare Part D, Medicaid managed care, exchange), rebate flow continues with different rules.

The PMPM admin fee is the replacement margin.

How do you price PMPM admin under cost-plus? Build the fee from the bottom up: cost-to-serve per member (claims processing, network management, member services, mail and specialty fulfillment), plus formulary and clinical-program cost, plus a target margin. Most cost-plus PBMs target $5–$15 PMPM depending on book complexity, versus $0.50–$2 under legacy rebate models.

What is a healthy specialty mix? Specialty scripts should be under 2% of total volume and 50%+ of total spend — that is the industry shape, not a target to manage to. The operating KPI is gross margin per specialty script and the share of specialty filled at owned vs network pharmacy, not raw mix.

How big is the Mark Cuban Cost Plus Drugs threat? Modest in absolute share, large in narrative and benchmarking power. Cuban's pricing posted publicly forces every employer RFP to ask the Big-3 to match acquisition-cost-plus-pharmacy-fee economics on generics, which is what TrueCost and Cost Clarity were built to answer.

Sources

Drug Channels Institute — The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
Pharmacy Benefit Management Institute (PBMI) — Trends in Drug Benefit Design
Federal Trade Commission — Interim Staff Report on Pharmacy Benefit Managers and the Express Scripts Consent Order (February 2026)
CVS Health — Form 10-K (FY2025)
The Cigna Group — Form 10-K (FY2025)
UnitedHealth Group — Form 10-K (FY2025)
Kaiser Family Foundation (KFF) — Pharmacy Benefit Managers and Federal Regulation Brief
National Community Pharmacists Association (NCPA) — Annual Digest
American Journal of Managed Care (AJMC) — Rebates, Reference Pricing, and 2026 PBM Reform Analyses
Frier Levitt — Cost-Plus Pharmacy Pricing and PBM Reform Briefings

Keep reading

Download:

### Direct Answer

The nine KPIs that actually run a Pharmacy Benefit Manager (PBM) business in 2027 are: **Scripts Dispensed (30-day adjusted)**, **Rebate Retention vs Pass-Through %**, **Generic Dispensing Rate (GDR %)**, **Specialty Pharmacy Mix %**, **Client Retention % (employer / health plan)**, **PMPM Admin Fee ($/member/month)**, **Formulary Adherence %**, **Mail-Order Penetration %**, and **340B Contract-Pharmacy Revenue ($)**. Together they answer the only three questions a PBM CFO cares about: are you growing claim volume, are you keeping the spread (and surviving the pivot to cost-plus), and are you retaining the employer and health-plan book under a 100% rebate pass-through regime.

> **TL;DR** — The Big-3 PBMs — CVS Caremark, Express Scripts, OptumRx — still process ~80% of U.S. Equivalent prescription claims, but the 2026 Consolidated Appropriations Act and the FTC settlement with Express Scripts force 100% rebate pass-through and a cost-plus reimbursement path that compresses traditional rebate-retention economics. Healthy GDR is 90%+, specialty mix is 50%+ of spend on under 2% of scripts, client retention should be 90%+ annually, and PMPM admin fees are migrating from $0.50–$2 (rebate-funded) to $5–$15 (cost-plus). Track claim volume and rejections daily, formulary adherence and GDR weekly, retention and PMPM monthly, and re-run the rebate-vs-cost-plus mix model quarterly — that is the operating cadence every PBM CFO is now running.

## Why PBMs Work Differently

**Three-sided economics on every script.** A PBM sits between plan sponsors (employers, health plans, Medicare Part D), drug manufacturers, and dispensing pharmacies. Revenue comes from four pools: admin fees from the plan sponsor (PMPM), rebate retention from manufacturers, spread on pharmacy reimbursement (paid pharmacy < charged plan), and dispensing margin from owned mail-order and specialty pharmacies. Historically the rebate and spread pools dwarfed PMPM fees — the 2026 reform package is the deliberate inversion of that mix. CVS Caremark, Express Scripts (Cigna Evernorth), and OptumRx (UnitedHealth) processed roughly 80% of U.S. 30-day adjusted claims in 2025: CVS Caremark at ~1.9B claims, Express Scripts pulling ahead after the Centene contract, OptumRx losing the CalPERS book to Caremark for 2026.

**Specialty pharmacy is the profit pool.** Drug Channels Institute pegged 2025 specialty pharmaceutical dispensing at ~$293.4B, up 9.6% year over year — and the top three specialty pharmacies, all owned by the Big-3 PBMs, captured roughly two-thirds of pharmacy-dispensed specialty revenue. Specialty scripts are under 2% of total volume but well over 50% of plan drug spend, and they carry the highest gross margin per script in the entire model. That is why every reform conversation in 2026 lands on the same vertical integration question: PBM, mail-order, specialty pharmacy, and (at CVS and Optum) the insurer itself.

**Regulatory reset to cost-plus and pass-through.** The Consolidated Appropriations Act of 2026 requires that ERISA group health plans receive 100% of manufacturer rebates from PBMs and their affiliated rebate aggregators. The FTC settlement with Express Scripts (February 2026) requires Express Scripts to move to cost-plus pharmacy reimbursement and eliminate spread pricing and rebate retention. CVS Caremark's "TrueCost" and OptumRx's "Cost Clarity" are the in-house responses, with full implementation targeted by 2028. The CFO question is no longer "how much rebate do we retain" — it is "what PMPM admin fee replaces it, and does the client still renew."

**Mark Cuban Cost Plus Drugs and the disintermediation threat.** Cuban's Cost Plus Drug Company has rewritten the price-transparency narrative — every generic posted at acquisition-cost-plus-15%-plus-$3-pharmacy-fee-plus-$5-shipping. The FTC interim reports flagged that six PBMs control more than 90% of the U.S. Prescription drug market. The effect is not Cuban taking 30% market share — it is forcing the Big-3 to underwrite explicit cost-plus product (Caremark TrueCost, OptumRx Cost Clarity) and to defend GDR economics inside their own books rather than at the network edge.

## The 9 KPIs, In Depth

**1. Scripts Dispensed (30-day adjusted, millions).** The volume number. Express Scripts processes ~2B+ 30-day adjusted claims annually, CVS Caremark ~1.9B (down 0.9% in 2025), OptumRx ~1.5B. Reported by channel (retail network, mail, specialty) and by line of business (commercial, Medicare Part D, Medicaid, exchange). Volume drift below -3% is the leading indicator of contract loss.

**2. Rebate Retention vs Pass-Through % (basis points retained).** Pre-reform, large PBMs retained 10–30% of negotiated rebates. Under the 2026 CAA and DOL rule, ERISA group plans receive 100% of manufacturer rebates from PBMs and their rebate aggregators. The KPI is now bifurcated: legacy retention book in run-off vs new pass-through plus PMPM admin fee book in run-on. The cash-flow gap is the single biggest source of 2026–2027 PBM margin compression.

**3. Generic Dispensing Rate (GDR %).** Generic fills divided by total prescriptions. Industry average is in the high 80s; best-in-class PBMs run 90%+. Every 1% increase in GDR is roughly a 5% reduction in gross plan drug spend, per published PBM benchmarking literature. The metric is contractually guaranteed on most large-employer PBM deals.

**4. Specialty Pharmacy Mix % (% of spend / % of scripts).** Specialty scripts are under 2% of total prescription volume but 50%+ of total spend, dispensing ~$293.4B in 2025 (up 9.6%). The top-3 specialty pharmacies, all PBM-owned, captured roughly two-thirds of pharmacy-dispensed specialty revenue. Specialty mix and specialty steerage to owned pharmacy is the single biggest gross-margin lever in the model.

**5. Client Retention % (employer / health plan, annual).** Annual retention of plan-sponsor lives. Best-in-class is 95%+; industry average is 90–93%. Major contract movements (Anthem leaving Express Scripts in 2019, CalPERS leaving OptumRx for Caremark in 2026) move billions in scripts in one renewal cycle. Track gross retention separately from net (which masks downsell).

**6. PMPM Admin Fee ($/member/month).** Admin fee per covered member per month. Historically $0.50–$2 PMPM under rebate-subsidized models. Under cost-plus and 100% pass-through, the replacement fee migrates to $5–$15 PMPM. The pricing pivot is the single most-scrutinized line item in every 2026–2027 RFP from Aon, Mercer, and WTW.

**7. Formulary Adherence % (preferred-drug fill rate).** Share of scripts filled at the preferred-formulary tier. Above 85% is healthy; below 75% means the formulary is leaking value through prior-auth failures, non-preferred fills, and physician override. Drives the manufacturer rebate yield that funds the rest of the model.

**8. Mail-Order Penetration % (90-day mail vs retail).** Share of maintenance-medication scripts dispensed through mail (90-day fills). Big-3 PBMs target 25–35% mail penetration on maintenance categories because mail margins are 200–400 bps higher than retail-network spread. Lower mail-order utilization usually correlates with a weaker incentive design at the plan-sponsor level.

**9. 340B Contract-Pharmacy Revenue ($).** Revenue from administering 340B contract-pharmacy programs for covered entities (DSH hospitals, FQHCs). The fastest-growing PBM-adjacent revenue stream, but also the most regulatory-volatile — manufacturer restrictions on 340B contract pharmacies (Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, etc.) have cut covered-entity revenue at hundreds of safety-net providers since 2023.

```mermaid
flowchart TD
    A[Plan Sponsor Contract] --> B[PMPM Admin Fee + Pass-Through Rebates]
    A --> C[Network of Retail Pharmacies]
    A --> D[Owned Mail-Order Pharmacy]
    A --> E[Owned Specialty Pharmacy]
    C --> F[Scripts Dispensed]
    D --> F
    E --> F
    F --> G{Generic vs Brand vs Specialty}
    G -->|Generic 90%| H[Lowest Cost High GDR Bonus]
    G -->|Brand 8%| I[Manufacturer Rebate Yield]
    G -->|Specialty under 2%| J[50%+ of Plan Spend]
    H --> K[Plan Sponsor Renewal Decision]
    I --> K
    J --> K
    K -->|Retain 90-95%| A
    K -->|Lose 5-10%| L[Volume Loss to Competitor PBM]
    J --> M[Specialty Steerage to Owned Pharmacy]
    M --> N[Highest Gross Margin Pool]
    N --> O[Reinvest in Formulary + Tech]
    O --> A
```

## Real Operators

**CVS Caremark (CVS Health)** is the volume leader — ~1.9B 30-day adjusted claims in 2025, ~31% market share, anchored to CVS retail, Caremark mail, and CVS Specialty, with CalPERS rejoining the book in 2026 and a "TrueCost" cost-plus pricing program launching system-wide. **Express Scripts (Cigna Evernorth)** is the share-gainer — added the Centene book, pulling ahead in 30-day equivalent claims, and is the named defendant in the FTC February 2026 settlement that mandates cost-plus reimbursement and the end of spread pricing. **OptumRx (UnitedHealth Group)** is the third pillar — ~20% market share, "Cost Clarity" cost-plus offering, lost CalPERS but added other large employer wins. **Humana Pharmacy Solutions** runs the captive PBM for Humana's Medicare Advantage book. **Prime Therapeutics** is the Blues-owned PBM serving ~30M Blue Cross Blue Shield lives. **Navitus Health Solutions** is the largest pass-through PBM, marketed as the transparent alternative. **MedImpact Healthcare Systems** is the largest privately held PBM, regional and health-plan focused. **Capital Rx** (now Judi Health) and **Rightway** are the venture-backed pass-through challengers winning mid-market employer business. **Mark Cuban Cost Plus Drug Company** is not a PBM in the traditional sense but the disintermediation pressure on Big-3 generic economics is real.

## Failure Modes

The four that kill PBMs. **(1) Rebate-retention denial** — modeling 2027 and 2028 P&L on legacy rebate retention assumptions when the CAA and FTC settlement explicitly forbid them is a 200–400 bps EBITDA miss. **(2) Specialty steerage litigation risk** — over-aggressive steerage to owned specialty pharmacy invites state attorney general action and ERISA fiduciary suits from plan sponsors. **(3) Client-concentration cliff** — when one health-plan or PBM-aggregator contract is 15%+ of book (Centene to Express Scripts, Anthem in prior cycles), a single non-renewal moves billions of scripts in one quarter. **(4) PMPM admin-fee underpricing** — replacing rebate retention with PMPM fees that are too low to recover the cost gap and discovering the gap only at the next true-up.

## Reporting Cadence

**Daily:** scripts processed, network rejections, prior-auth turnaround, specialty pharmacy fill rates. **Weekly:** GDR by client, formulary adherence by client, mail-order penetration, member-services service-level agreements. **Monthly:** PMPM admin fee vs target by client, specialty mix and gross margin by therapy area, rebate accrual vs pass-through actuals, client-level P&L. **Quarterly:** retention pipeline (renewal/RFP), regulatory exposure (FTC, state PBM laws, CMS Part D guidance), 340B contract pipeline, full P&L by line of business for the earnings call.

```mermaid
flowchart TD
    A[Daily Telemetry] --> B[Scripts + Rejections + PA Turnaround + Specialty Fill]
    B --> C[Weekly Operating Review]
    C --> D[GDR by Client + Formulary Adherence + Mail Penetration + SLAs]
    D --> E[Monthly Business Review]
    E --> F[PMPM Actual vs Target + Specialty Margin + Rebate Pass-Through + Client P&L]
    F --> G[Quarterly Earnings + Board]
    G --> H[Retention Pipeline + Regulatory + 340B + LOB P&L]
    H --> I[Re-forecast PMPM Pricing + Specialty Steerage + Cost-Plus Mix]
    I --> A
```

## 30/60/90 Day Plan

**Days 1–30:** instrument the nine KPIs end-to-end. Reconcile 30-day adjusted claim counts across the adjudication platform (RxClaim or equivalent), finance, and the rebate-aggregator reporting — they will disagree on day one and the reconciliation gap is the first finding. Establish GDR, specialty mix, and PMPM-actual baselines per client.

**Days 31–60:** build the cost-plus migration model. Run client-by-client P&L under three scenarios: legacy rebate-retention, 100% pass-through with current PMPM fee, and 100% pass-through with re-priced PMPM at $8–$12. Identify the bottom-decile clients where the math does not work and brief sales on re-pricing or non-renewal.

**Days 61–90:** stand up the regulatory exposure dashboard. Map every contract against CAA 2026, the FTC Express Scripts consent order, state PBM transparency laws (Texas, Florida, Iowa, Oklahoma, Arkansas), and CMS Part D guidance. Re-baseline 340B contract-pharmacy revenue under updated manufacturer restrictions and present the new operating model to the CFO with monthly checkpoints.

## FAQ

**Is rebate retention dead in 2027?** Inside ERISA group health, effectively yes — the CAA 2026 100% pass-through mandate plus the FTC Express Scripts settlement collapse the traditional retention economics. Outside ERISA (Medicare Part D, Medicaid managed care, exchange), rebate flow continues with different rules. The PMPM admin fee is the replacement margin.

**How do you price PMPM admin under cost-plus?** Build the fee from the bottom up: cost-to-serve per member (claims processing, network management, member services, mail and specialty fulfillment), plus formulary and clinical-program cost, plus a target margin. Most cost-plus PBMs target $5–$15 PMPM depending on book complexity, versus $0.50–$2 under legacy rebate models.

**What is a healthy specialty mix?** Specialty scripts should be under 2% of total volume and 50%+ of total spend — that is the industry shape, not a target to manage to. The operating KPI is gross margin per specialty script and the share of specialty filled at owned vs network pharmacy, not raw mix.

**How big is the Mark Cuban Cost Plus Drugs threat?** Modest in absolute share, large in narrative and benchmarking power. Cuban's pricing posted publicly forces every employer RFP to ask the Big-3 to match acquisition-cost-plus-pharmacy-fee economics on generics, which is what TrueCost and Cost Clarity were built to answer.

## Sources

- Drug Channels Institute — The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
- Pharmacy Benefit Management Institute (PBMI) — Trends in Drug Benefit Design
- Federal Trade Commission — Interim Staff Report on Pharmacy Benefit Managers and the Express Scripts Consent Order (February 2026)
- CVS Health — Form 10-K (FY2025)
- The Cigna Group — Form 10-K (FY2025)
- UnitedHealth Group — Form 10-K (FY2025)
- Kaiser Family Foundation (KFF) — Pharmacy Benefit Managers and Federal Regulation Brief
- National Community Pharmacists Association (NCPA) — Annual Digest
- American Journal of Managed Care (AJMC) — Rebates, Reference Pricing, and 2026 PBM Reform Analyses
- Frier Levitt — Cost-Plus Pharmacy Pricing and PBM Reform Briefings

Was this helpful?

Related in the library